A question from the latest conference call
Our next question is from [Terry Flynn]. -------------------------------------------------------------------------------- Unidentified Analyst, [23] -------------------------------------------------------------------------------- I just wanted to check in on the SleepCheck app. Were you planning on, I suppose, reapplying to have that accredited as a diagnostic tool and not just a screening tool? -------------------------------------------------------------------------------- Anthony Keating, ResApp Health Limited - CEO, MD & Director [24] -------------------------------------------------------------------------------- So at this point, no. So at this point, we believe that as a screening tool, we have the best chance of making a larger impact in the general population. So I think you need to -- what's important to realize in that, there are 2 different opportunities in many health care situations. So one is a screening opportunity, which is screening a large number of people and identifying those people who are at risk. And then obviously, the second part, which is the diagnostics part, which is the formal diagnosis to lead to treatment. So our target with SleepCheck is the first, is to mass screen large numbers of people. That's the mass consumer market products to identify risk. And so the second part there, we may end up towards, in the longer term, moving through a diagnostic product. But we believe that the commercial opportunity today is actually the mass market. And that is map screening and identifying risk. So I would say rather than being a regulatory decision about whether it's classed as a screening tool or a diagnostic tool. It's actually a business decision. We believe that the best business opportunity here is screening -- mass screening direct-to-consumer product here
Regards
Bloky
Expand
